1Associate Professor, Department of Oral Medicine and Radiology, S.C.B. Dental College & Hospital, Cuttack, India
2Associate Professor, Department of Oral Pathology & Microbiology, I.D.S., Siksha “O” Anusandhan, Deemed to be university, BBSR, Odisha, India
3Post graduate student, Department of Oral Medicine and radiology, S.C.B. Dental College and Hospital, Cuttack, Odisha, India
4Professor, Department of Otorhinolaryngology, IMS and SUM hospital, Siksha “O” Anusandhan, Deemed to be University, K8, Kalinganagar, Bhubaneswar, Odisha, India
5Assistant professor, Department of Medical Research Laboratory, IMS and SUM hospital, Siksha “O” Anusandhan, Deemed to be University, Kalinganagar, Bhubaneswar-751003, Odisha, India
6Professor, Department of Prosthodontia, C.D.C.R.I., Rajnandgaon, Chhattisgarh, India
7Assistant Surgeon, Department of Oral Medicine, S.C.B. Dental College & Hospital, Cuttack, India
Online published on 13 December, 2018.
Trigeminal neuralgia (TN) is one of the ancient neuropathic disorders which torments a significant proportion of the population. Although Carbamazepine is the first line drug of choice in the treatment of this debility, cases falling into the domain of intractable neuralgia fail to respond to maximum tolerable doses of the drug. In such cases, Oxcarbazepine (OXC) may be given more preference owing to the minor risk for drug interactions and its better tolerability in comparison with CBZ. This study was designed to study the therapeutic effectiveness of OXC in intractable TN using Efficacy index of Clinical Global Impressions (CGI) score, also accounting for the adverse effects using Liverpool Adverse Events Profile.
Intractable TN, Clinical Global Impressions (CGI) score, Efficacy index, Liverpool Adverse Events Profile
